Literature DB >> 12234022

Health-related quality of life measurements and studies in rheumatoid arthritis.

Deborah P Lubeck1.   

Abstract

BACKGROUND: Rheumatoid arthritis (RA) is a major cause of disability and impairment of health-related quality of life (HRQOL) in the United States. Increasingly, HRQOL assessments are becoming part of a package of materials reviewed by managed care providers in making formulary and reimbursement decisions.
OBJECTIVE: To help managed care administrators understand how to interpret and apply the results of HRQOL assessment scales.
METHODS: Several patient-reported instruments in common use in RA were reviewed, including the Health Assessment Questionnaire (HAQ), Modified HAQ, Arthritis Impact Measurement Scale, and the 36-item Short-Form Health Survey.
RESULTS: These self-assessment scales help improve patient/physician communication and thus enable better treatment decision-making. The scales can also aid managed care administrators in evaluating the efficacy and the financial benefits of therapies. The HAQ was one scale that stood out as being short, easy to administer, and disease-specific for RA.
CONCLUSIONS: Self-assessment reports, such as the HAQ, provide key data on disability and HRQOL from the patient's perspective. The information so gained enables the clinician to select the most cost-effective therapies and interventions that slow disease progression, maintain functional status, and improve HRQOL.

Entities:  

Mesh:

Year:  2002        PMID: 12234022

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  11 in total

1.  Quality of life in Indian patients with rheumatoid arthritis.

Authors:  Gurdesh S Bedi; Nikhil Gupta; Rohini Handa; Hemraj Pal; R M Pandey
Journal:  Qual Life Res       Date:  2005-10       Impact factor: 4.147

2.  Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study.

Authors:  M E Weinblatt; E C Keystone; D E Furst; A F Kavanaugh; E K Chartash; O G Segurado
Journal:  Ann Rheum Dis       Date:  2005-11-24       Impact factor: 19.103

3.  Health-related quality of life in Moroccan patients with rheumatoid arthritis.

Authors:  Yousra Ibn Yacoub; Bouchra Amine; Assia Laatiris; Najia Hajjaj-Hassouni
Journal:  Clin Rheumatol       Date:  2012-08-18       Impact factor: 2.980

Review 4.  Quality-of-life assessment in rheumatoid arthritis.

Authors:  Anthony S Russell
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 5.  Sociodemographic differences in quality of life in rheumatoid arthritis.

Authors:  Erik J Groessl; Theodore G Ganiats; Andrew J Sarkin
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

6.  Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study.

Authors:  Vibeke Strand; Gerd R Burmester; Sarika Ogale; Jenny Devenport; Ani John; Paul Emery
Journal:  Rheumatology (Oxford)       Date:  2012-06-28       Impact factor: 7.580

Review 7.  Measurement properties of physical function scales validated for use in patients with rheumatoid arthritis: a systematic review of the literature.

Authors:  Martijn A H Oude Voshaar; Peter M ten Klooster; Erik Taal; Mart A F J van de Laar
Journal:  Health Qual Life Outcomes       Date:  2011-11-07       Impact factor: 3.186

8.  Modeling rheumatoid arthritis using different techniques - a review of model construction and results.

Authors:  Stefan Scholz; Thomas Mittendorf
Journal:  Health Econ Rev       Date:  2014-09-16

9.  Effects of low-dose tacrolimus therapy in combination with methotrexate in patients with methotrexate-refractory rheumatoid arthritis.

Authors:  Takeo Isozaki; Michihito Sato; Ryo Takahashi; Kuninobu Wakabayashi; Nobuyuki Yajima; Yusuke Miwa; Masao Negishi; Hirotsugu Ide; Tsuyoshi Kasama
Journal:  Open Access Rheumatol       Date:  2010-07-03

10.  Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.

Authors:  Zhanguo Li; Yuan An; Houheng Su; Xiangpei Li; Jianhua Xu; Yi Zheng; Guiye Li; Kenneth Kwok; Lisy Wang; Qizhe Wu
Journal:  Int J Rheum Dis       Date:  2018-01-04       Impact factor: 2.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.